Investing News NetworkMay 15, 2024 (TheNewswire) Calgary, Alberta TheNewswire - May 15, 2024.  Ocumetics Technology Corp. (' Ocumetics ' or the ' Corporation ') (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a non-brokered private placement of secured convertible debentures having an aggregate face value principal amount of up to $4,000,000 (the ' Principal ').

投资新闻网2024年5月15日（TheNewswire）阿尔伯塔省卡尔加里市TheNewswire-2024年5月15日。Ocumetics Technology Corp.（“Ocumetics”或“Corporation”）（TSXV:OTC）（OTCQB:OTCFF）（FRA:2QBO）宣布，其计划完成非经纪私募的有担保可转换债券，总面值本金金额高达4000000美元（“本金”）。

The debentures will be subject to an original issue discount of 6%, resulting in net available funds to the Corporation of up to $3,760,000 (the ' Net Proceeds ').   Debentures will bear interest at rate of 18% per annum, compounded annually.  The Debentures will mature, and Principal and interest will be payable by the Corporation, on the date which is two years from the date of issue.

这些债券将享有6%的原始发行折扣，从而使公司的可用资金净额高达3760000美元（“净收益”）。债券的年利率为18%，每年复利。债券将于发行之日起两年到期，公司将支付本金和利息。

The Corporation may prepay the indebtedness under the debentures at any time upon ninety (90) days prior written notice, without penalty. Principal will be convertible at the option of the holder into common shares of the Corporation at a conversion price of $0.32 per share.  Interest will be convertible into common shares of the issuer pursuant to shares for debt applications, from time to time, at the option of the debenture holders.

公司可在提前九十（90）天发出书面通知的情况下随时提前偿还债券项下的债务，无需罚款。本金将根据持有人的选择以每股0.32美元的转换价格转换为公司的普通股。根据债券持有人的选择，利息将根据债务申请股份不时转换为发行人的普通股。

The Debentures will be secured by a general security agreement on the personal property of the Corporation. The Debentures and the common shares issuable upon the conversion of the Debentures will be subject to a four month hold period.  Completion of the offering is subject to the final approval of the TSX Venture Exchange.

债券将由公司个人财产的一般担保协议担保。债券转换后可发行的债券和普通股将有四个月的持有期。本次发行的完成取决于TSX风险交易所的最终批准。

100% of the Net Proceeds are expected to be used to fund the Corporation's first in-human clinical trials and for ongoing research and development.  Although the Corporation intends to use the proceeds of the offering as described above, the a.

预计净收益的100%将用于资助该公司的首次人体临床试验以及正在进行的研究和开发。虽然公司打算使用上述发行收益，但a。